Analytical Data
-
基因名
IL4I1
- Application
-
别名
IL4I1；FIG1；L-amino-acid oxidase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96RQ9
-
表达区间
30-513aa
-
氨基酸序列
QDPFEKCMQDPDYEQLLKVVTWGLNRTLKPQRVIVVGAGVAGLVAAKVLSDAGHKVTILEADNRIGGRIFTYRDQNTGWIGELGAMRMPSSHRILHKLCQGLGLNLTKFTQYDKNTWTEVHEVKLRNYVVEKVPEKLGYALRPQEKGHSPEDIYQMALNQALKDLKALGCRKAMKKFERHTLLEYLLGEGNLSRPAVQLLGDVMSEDGFFYLSFAEALRAHSCLSDRLQYSRIVGGWDLLPRALLSSLSGLVLLNAPVVAMTQGPHDVHVQIETSPPARNLKVLKADVVLLTASGPAVKRITFSPPLPRHMQEALRRLHYVPATKVFLSFRRPFWREEHIEGGHSNTDRPSRMIFYPPPREGALLLASYTWSDAAAAFAGLSREEALRLALDDVAALHGPVVRQLWDGTGVVKRWAEDQHSQGGFVVQPPALWQTEKDDWTVPYGRIYFAGEHTAYPHGWVETAVKSALRAAIKINSRKGPASD
-
分子量
61.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL4I1, or Interleukin 4 Inducible Protein 1, is a protein that has garnered significant interest in immunology and cancer research due to its role in modulating the immune response. Initially identified as an interferon-gamma-inducible protein, IL4I1 is known for its ability to catabolize tryptophan through the kynurenine pathway, which can influence T cell activation and enhance immune tolerance. This enzymatic activity has implications in various diseases, including cancer, where tumors often exploit immune evasion strategies. Recent studies have demonstrated that IL4I1 expression can be upregulated in certain cancers, thereby contributing to the immunosuppressive tumor microenvironment. Given its dual role in both promoting immune tolerance and potentially aiding tumor progression, researchers are keen to explore the therapeutic potentials of targeting IL4I1. By generating recombinant IL4I1 protein, scientists aim to elucidate its precise functions, validate its role as a biomarker for cancer prognosis, and evaluate its potential as a target for immunotherapy. Understanding IL4I1's mechanism of action may lead to novel strategies to enhance anti-tumor immunity and improve therapeutic outcomes in cancer patients. Hence, the study of IL4I1 and its recombinant forms stands at the intersection of immunology and oncology, offering pathways for innovative approaches to treating malignancies through modulation of immune responses.
